



Detection of Carbapenemase-Producing *Escherichia coli* and *Klebsiella pneumoniae* Implicated in Urinary Tract Infection

Onyinye Lovette Nومه^a, Obodoechi Ijeoma Federica^b,
Ofonmbuk Victor Joseph^c, Ezeh Chinonyelum Moneth^d,
Rebecca Chinenye Ogba^{a,e}, Ohadoma Angela Nkechi^f,
Ikemesit Udeme Peter^{a,b*}, Peace Oluchi Akpu^a,
Christiana Inuaesiet Edemekong^g
and Ifeanyichukwu Romanus Iroha^a

^a Department of Applied Microbiology, Faculty of Science, Ebonyi State University, Abakaliki, P.M.B. 53, Nigeria.

^b Department of Public Health, Faculty of Health Technology and Engineering, Federal College of Dental Technology and Therapy, Trans-Ekulu, P.M.B. 01473, Enugu, Nigeria.

^c Department of Science Laboratory Technology, Heritage Polytechnic Ikot Udoata, Eket, Akwa Ibom State, Nigeria.

^d Department of Dental Nursing, Faculty of Dental Health, Federal College of Dental Technology and Therapy, Trans-Ekulu, P.M.B. 01473, Enugu, Nigeria.

^e Department of General Studies, Science and Technology, Federal Polytechnic, Ohodo, P.M.B. 01801, Enugu, Nigeria.

^f Department of Dental Therapy, Faculty of Dental Health, Federal College of Dental Technology and Therapy, Trans-Ekulu, P.M.B. 01473, Enugu, Nigeria.

^g Department of Biotechnology, Faculty of Pure and Applied Science, Federal College of Dental Technology and Therapy, Trans-Ekulu, P.M.B. 01473, Enugu, Nigeria.

Authors' contributions

This work was carried out in collaboration among all authors. Authors OLN, OIF and RCO wrote the protocol. Authors IRI, ECM, OAN and IUP wrote the first draft of the manuscript. Authors CIE, OVJ, POA and IRI managed the molecular analyses of the study. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/AJRID/2023/v12i1234

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/95266>

*Corresponding author: E-mail: ikemesitpeter@gmail.com;

ABSTRACT

Background and Objectives: Carbapenemase-producing bacteria are super bugs that make Urinary Tract Infections (UTIs) difficult to treat with drug of last resort such as carbapenem and other antibiotic thus limiting the treatment options. Carbapenemase production is increasing in clinical isolates of *E. coli* and *K. pneumoniae*, their potential to spread widely among patients necessitates molecular detection of carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae* implicated in Urinary Tract Infection.

Methodology: A total of twelve (12) non-repeated clinical isolate of *Escherichia coli* (E1, E2, E3, E4, E5, E6, E7) and *Klebsiella pneumoniae* (K8, K9, K10, K11, K12) were selected based on their *in vitro* phenotypic resistant to carbapenem antibiotics from patients diagnosed with urinary tract infection at Alex Ekwueme Federal University Teaching Hospital, Abakaliki (AE-FEUTHA) Ebonyi State Nigeria. *Escherichia coli* and *Klebsiella pneumoniae* were further confirmed using standard routine microbiological technique for isolation and identification of bacteria. *Escherichia coli* and *Klebsiella pneumoniae* strains were further screen for carbapenemase-producing gene by PCR specific primer.

Result: PCR analysis with specific primer for carbapenemase gene revealed the presence and predominant of bla_{KPC} in *Escherichia coli* and *Klebsiella pneumoniae* 12(100 %) followed by bla_{NDM} 11(91.7 %), bla_{IMP} 7(58.3 %) and bla_{VIM} 2(16.7) as the least carbapenemase-producing gene in *Escherichia coli* and *Klebsiella pneumoniae*. bla_{KPC} was predominant in *Escherichia coli* 7(58.3 %) followed by bla_{NDM} 6(50.0 %) and bla_{IMP} 5(41.7 %) while both bla_{OXA} and bla_{VIM} (16.7 %) were the least detected carbapenemase gene. *Klebsiella pneumoniae* harbor high proportion of bla_{NDM} and bla_{KPC} both recording 5(41.7 %) followed by bla_{OXA} and bla_{IMP} both recording 2(16.7 %) but bla_{VIM} gene was not identified in *Klebsiella pneumoniae*.

Conclusion: The current findings highlight the occurrence of carbapenemase-producing gene in *Escherichia coli* and *Klebsiella pneumoniae* implicated in UTI. Since these genes are carried on the bacteria plasmid there is a tendency of cross-species dissemination over time. The detection of carbapenemase-producing gene call for prompt epidemiological surveillance and preventive strategies to limit the spread of these carbapenemase resistant genetic determinant and the need for antibiotic susceptibility testing of available antibiotic agent.

Keywords: Urinary tract infection; carbapenemase-producing; *Escherichia coli*; *Klebsiella pneumoniae*.

1. INTRODUCTION

A carbapenemase-producing *Escherichia coli* or *Klebsiella pneumoniae* is a bacterium that is resistant to carbapenem antibiotics in susceptibility testing or has a carbapenemase gene [1]. In 2017, the World Health Organization designated carbapenemase-producing *E. coli* and *Klebsiella pneumoniae* as 'critical' and 'high priority pathogens' [1,2]. Since then, carbapenem resistant *Escherichia coli* and *Klebsiella pneumoniae* is a growing concern worldwide [3,4] due to rapid evolution and spread of carbapenemase producing genotype e.g., New Delhi metallo- β -lactamase (bla_{NDM}),

Imipenemases (bla_{IMP}), Verona integron Metallo-beta-lactamase (bla_{VIM}), Oxacillinase (bla_{OXA}) and *Klebsiella pneumoniae* carbapenemase (bla_{KPC}) which are increasingly being reported among health care associated complicated UTIs owing to their ability to truncates the action of carbapenem and other beta-lactam antibiotics [4,5,6]. Urinary Tract Infections are infectious diseases commonly caused by enterobacteriaceae such as *Escherichia coli* and *Klebsiella pneumoniae* [4,7,8]. These bacteria invade and colonize any part of the urinary tract [4,9] producing symptoms such as fever, burning sensations while urinating, lower abdominal pain (LAP), itching, blister and ulcer formation in the genital area, genital and suprapubic pain, and

pyuria. These are generally determined by the age of the person infected and the location of the infected urinary tract. UTIs are common bacterial infections that affect approximately 150 million people worldwide each year, posing a significant financial burden on the community and health-care system [6]. The prevalence and rapidly evolving carbapenemase gene from *Escherichia coli* and *Klebsiella pneumoniae* make UTI difficult to treat with drug of last resort such as carbapenem thus limiting the treatment options. These resistance genes containing bacteria are super bugs and are termed as carbapenemase producing *Escherichia coli* and *Klebsiella pneumoniae* challenging the empiric treatment of UTI worldwide. Globally, these gene is progressively spreading among clinical isolates of *E. coli* and *K. pneumoniae* widely amongst patients and has necessitate the need for molecular investigation of carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae* implicated in Urinary Tract Infection.

2. MATERIALS AND METHODS

2.1 Characterization of *Escherichia coli* and *Klebsiella pneumoniae*

Non-repeated clinical isolate of *Escherichia coli* (E1,E2,E3,E4,E5,E6,E7) and *Klebsiella pneumoniae* (K8,K9,K10,K11,K12) were collected from selected patients diagnosed with Urinary tract infection at Alex Ekwueme Federal University Teaching Hospital, Abakaliki (AE-FEUTHA) Ebonyi State, Nigeria. The clinical isolates were selected based on their *in vitro* phenotypic resistant to carbapenem antibiotics. All the information obtained from the studied subjects was coded to maintain confidentiality and in accordance with the World Medical Association (WMA) declaration of Helsinki on the principles for medical research [10,11]. The twelve clinical isolate of *Escherichia coli* and *Klebsiella pneumoniae* were further confirmed using standard routine microbiological Technique for identification and characterization of bacteria [12,13].

2.2 Molecular Screening for Carbapenemase-producing Genes Using Polymerase Chain Reaction (PCR)

2.2.1 DNA extraction

Genomic DNA Extraction of *Escherichia coli* and *Klebsiella pneumoniae* was performed using ZR Fungal/Bacterial DNA Miniprep™

(Manufactured by Zymo research, cat number: D6005) kit according to the manufacturer's protocol. Exactly 2 ml of bacterial cells broth was added to a ZR Bashing TM lysis tube and 750 µg lysis solutions was added to it. This was secured in a bead fitted with 2 ml tube holder assembly and processed at a maximum speed for 5 minutes. The ZR bashing bead Tm lysis tube was centrifuged at > 10,000 x g for 1 minute. Up to 400 µg of supernatant was transferred to a Zygomo-Spin TM IV Filter in a collection tube and centrifuged at 7,000 x g for 1 minute. Exactly 1,200 µg of bacterial DNA binding buffer was added to the filtrate in the collection tube. Exactly 800 ul of the mixture from step 5 was transferred to a Zygomo-spin™ IIC column in a collection tube and centrifuged at 10,000 x g for 1 minute. The flow through from the collection tube was discarded. Then 200 ul DNA Pre-washed buffer was added to the Zymo-Spin TM IIC column in a new tube collection and centrifuged at 10,000 x g for 1 minute. About 200 µg of bacterial DNA Buffer was added to the Zymo-Spin TM IIC column and centrifuged at 10,000 x g for 1 minute. The Zymo-Spin TM IIC column was transferred to a clean 1.5 ml micro-centrifuge tube and 100 µl (35 µl minimum) DNA was added directly to the column matrix. Centrifuge was done at 10,000 x g for 30 seconds to elute DNA [11,14].

2.2.2 Electrophoresis for DNA and PCR product

Exactly 1 g of agarose was measured (for DNA) and 2 g of agarose for PCR products. Agarose powder was mixed with 100 ml 1xTAE in a microwave flask. This was microwaved for 1-3 min until agarose completely dissolved. The agarose solution was allowed to cool to about 50 °C. Then 10 µg EZ vision DNA stain was added. The agarose was poured into a gel tray with the well comb in place. The newly poured gel was placed at 4°C for 10-15 mins until it has completely solidified [11,14].

2.2.3 Loading samples and running an agarose gel

A loading buffer was added to each DNA sample of PCR products. Once it got solidified the agarose gel was placed into the gel box (electrophoresis unit). The gel box was filled with 1xTAE buffer until the gel was covered. A molecular weight ladder was carefully loaded into

Table 1. Primer Sequences use for detection of Carbapenemase-producing resistance genes [15,16]

Primers	Sequence (5'–3'),	Amplicon size (bp)
<i>bla</i> _{KPC}	F:CGTCTAGTTCTGCTGTCTTG R:CTTGTCATCCTTGTTAGGCG	500
<i>bla</i> _{OXA}	F:GCGTGGTTAAGGATGAACAC R:CATCAAGTTCAACCCAACCG	550
<i>bla</i> _{IMP}	F:CTACCGCAGCAGAGTCTTTGC R:ACAACCAGTTTTGCCTTACC	232
<i>bla</i> _{NDM}	F:GCAGCTTGTCGGCCATGCGGGC R:GGTCGCGAAGCTGAGCACCGCAT	800
<i>bla</i> _{VIM}	F:AAAGTTATGCCGCACTCACC R:TGCAACTTCATGTTATGCCG	250

the first lane of gel and the samples were carefully loaded into the additional wells of gel. The gel was run at 80-150 V for about 1-1.5 h. The power was turned off, and the electrodes disconnected from the power source and then the gel was carefully removed from the gel box. The DNA fragments or PCR fragments was visualized under UV trans-illuminator [15,16].

2.2.4 PCR mix components and Cycling conditions

The PCR mix components was made up of 12.5 µl of Taq 2 x Master Mix from New England Biolabs (M0270); 1 µl each of 10µm forward and reverse primer (Invitrogen, U.S.A™) (Table 1); 2 µl of DNA template and then made up with 8.5 µL Nuclease free water. The PCR reactions was executed as previously described by Edemekong et al. [14]. Cycling conditions for amplification of carbapenemase resistance genes was adopted as previously described in other studies [15,16,17].

3. RESULTS

3.1 Molecular Detection of Carbapenemase-producing Gene in UTI Patients Harboring Uropathogenic *Escherichia coli* and *Klebsiella pneumoniae*

The higher proportion of carbapenemase-producing gene in all the bacterial isolate in this study was *bla*_{KPC} 12(100 %), followed by *bla*_{NDM} 11(91.7 %), *bla*_{IMP} 7(58.3 %) and *bla*_{VIM} 2(16.7). The *bla*_{KPC} was predominant in *Escherichia coli* 7(58.3 %) followed by *bla*_{NDM} 6(50.0 %) and *bla*_{IMP} 5(41.7 %) while both *bla*_{OXA} and *bla*_{VIM} (16.7 %) were the least detected carbapenemase gene. *Klebsiella pneumoniae* harbored higher

proportion of *bla*_{NDM} and *bla*_{KPC} both recording 5(41.7 %) followed by *bla*_{OXA} and *bla*_{IMP} both recording 2(16.7 %) while *bla*_{VIM} gene was not detected as shown in Table 2.

4. DISCUSSION

The molecular detection of carbapemase-producing genes among the isolates in this study revealed that the *bla*_{KPC} in *Escherichia coli* and *Klebsiella pneumoniae* accounted for 12(100 %). The plasmid-encoded KPC enzyme was first identified in a *K. pneumoniae* isolate from North Carolina, USA [18]. Since 2001, these isolates have spread across the USA, with reports of KPC-producers across 38 states [19]. Although KPC-producers are now being identified at an alarming rate across Europe, facilitated mostly by clonal dissemination, to the best of our knowledge there is no published report of *bla*_{KPC}-positive isolates from this area of study (Abakaliki) while elsewhere of Nigeria such as Maiduguri, northeast Nigeria and in two Chinese studies, *bla*_{KPC} has been reported as the most predominant carbapenemase gene [16,20,21].

The *bla*_{NDM} 11(91.7 %) was the second most predominant carbapenem gene, despite the fact that NDM-1 bearing gene is increasingly reported worldwide, NDM-1 has been most commonly identified in *E. coli* and *K. pneumoniae* [6,21,22,23,24,25] as evidence in this study. This study inferred that the frequent switch of predominant carbapenemase genotype might result from introduction of those strains from different sources (like some regions, animals or food) with different popular carbapenemase genes, or transformation of some mobile elements that carried carbapenemase genes between species [26,27,28]. Although the driving mechanism for this situation remains unclear, it.




Fig. 1. Gel showing Genomic DNA Extracted from Clinical Isolates of *E. coli* and *Klebsiella pneumonia*

Table 2. Molecular detection of Carbapenemase-producing gene in Uropathogenic *Escherichia coli* and *Klebsiella pneumoniae*

Carbapenemase class	Genes	Uropathogenic (n=12)		
		E1-7 (%)	K8-12 (%)	Frequency (%)
A	<i>bla_{KPC}</i>	7(58.3)	5(41.7)	12(100)
B	<i>bla_{IMP}</i>	5(41.7)	3(25.0)	7(66.7)
B	<i>bla_{VIM}</i>	2(16.7)	0(0.0)	2(16.7)
B	<i>bla_{NDM}</i>	6(50.0)	5(41.7)	11(91.7)
D	<i>bla_{OXA}</i>	2(16.7)	2(16.7)	4(33.3)

Key: n-Number of isolate, *bla_{KPC}*-*Klebsiella pneumoniae* carbapenemase, *bla_{IMP}*-Imipenemases, *bla_{VIM}*-Verona integron Metallo-beta-lactamase, *bla_{NDM}*-New Delhi Metallo-beta-lactamase, *bla_{OXA}*-Oxacillinase

further highlights the importance of long-term active resistance surveillance of CR-isolate in community and hospital setting. Although existing literature highlight India and Pakistan being considered to be the main reservoir for NDM-producing isolates which were detected in this study, it has been suggested that the Middle East region might be a secondary reservoir for the spread of *bla_{NDM-1}* isolates as there is a high frequency of population movement between Saudi Arabia and the Indian subcontinent [29,30,31,32]. This study speculate that population movement where *bla_{KPC}* and *bla_{NDM}* is endemic and was first identified, might explain the high occurrence of isolates with *bla_{KPC}* resistance gene in this setting, although the absence of data on patient travel history to those endemic area precludes any firm conclusions being drawn *bla_{OXA}* recorded 4(33.3 %) but were not predominantly detected as commonly speculated as being the most frequently detected gene in *K. pneumoniae*, *E. coli* and other Enterobacterales. The production of OXA is one of the main

mechanisms of carbapenem resistant in most bacteria. This finding correspond with Alizadeh et al. [33] who reported percentage of carbapenemase genes in *K. pneumoniae*; *bla_{OXA}*-like (78%) while different *E. coli* clones have successfully emerged in the world; examples are *E. coli* O15:K52:H1-D of sequence type 393 (ST393), *E. coli* ST131, and *E. coli* ST38, which is characterized by the production of the OXA β-lactamase and is related to strains of the Mediterranean basin countries [34,35]. The role of *bla_{OXA}* strain in UTI in this study can't be underestimated but virulence has been linked to the presence of *bla_{OXA-48}* in clinical *E. coli* and *K. pneumoniae* isolates. Several studies reported on clinical isolates with an unusual high lethality in murine infection models as well as the presence of genes associated with virulence or host colonization, but the specific role of OXA-48 had not been addressed [36,37,38].

To the best of our knowledge this study tends to be the first to report the present of *bla_{VIM}* 2(16.7)

producing *E. coli* in Abakaliki while isolate positive for the *bla_{VIM}* gene has been found by other researchers [20,23,39,40,41] and in one study it was located on an *Incl1* plasmid of a novel sequence type (ST 297) [42]. Since this gene are carried on plasmid there is a tendency of cross-species dissemination over time.

Although, *bla_{IPM}* 66.7 % was reported in this finding, notably this genes is not commonly reported among *E. coli* and *K. pneumoniae* but the co-existence of Amber class A such as *bla_{IPM}* with Amber class B and D are known to confer resistance to oxyiminocephalosporins (ceftriaxone and ceftazidime) and cephamycins (cefoxitin), and transfer of the resistance has been confirmed by transconjugation [43,44,45]. Therefore, it should be noted that carbapenemase reservoirs in healthcare workers, patients, or the hospital environment may be a principal mode of spread in nosocomial outbreaks.

5. CONCLUSION

This findings echoes a successfully emergence of carbapenemase producing genes in *E. coli* and *K. pneumoniae* associated UTI. Although, *bla_{VIM}* gene was absent in *K. pneumoniae*, the virulence role of carbapenemase-producing genes in UTI in this study can't be underestimated as they can lead to persistence of UTI among patients due to treatment failure. The detection of carbapenemase gene call for prompt epidemiological surveillance and preventive strategies to limit the spread of these carbapenemase resistant genetic determinant and the need for antibiotic susceptibility testing of available antibiotic agent.

CONSENT

As per international standard or University standard, patients' written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

In compliance with international standard or University standard written ethical approval with number SMOH/ERC/042/21 has been collected and preserved by the author (s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Nomeh OL, Chukwu EB, Ogba RC, Akpu PO, Peter IU, Nwuzo AC, Iroha IR. Prevalence and Antibigram Profile of Carbapenem-resistant *Escherichia coli* and *Klebsiella pneumoniae* among Patients with Urinary Tract Infection in Abakaliki, Nigeria. Int J Pathogen Res. 2022; 11(3):14-28
2. World Health Organization (WHO). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics; 2017. Available: <https://www.who.int/medicines/publications/WHO-PPL-Short>.
3. Nordmann P. Current situation on spread of metallo- β -lactamases in enterobacteriaceae [Abstract C1-1331]. In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston: American Society for Microbiology; 2010.
4. Suwaiba M, Dadah AJ, Sanusi SB. Prevalence of Carbapenem resistant *Escherichia coli* and *klebsiella pneumoniae* in urine samples of patients attending selected general hospitals within Kaduna Metropolis. Sci. World J. 2020;15(4):23-67.
5. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, eds. Principles and Practice of Infectious Diseases, 8th Edition, Philadelphia, USA: Elsevier Saunders. 2014:886-913.
6. Nasir F, Khan MI, Kashif S, Uddin F, Naseer A, Masood S. Prevalence of ESBLs secreting and carbapenem-resistant *E. coli* from urinary tract infection. Rawal Med J. 2021;46:3-23.
7. Tenney J, Hudson N, Alnifaidy H, Li JTC, Fung KH. Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: A systematic literature review. Saudi Pharm J. 2018;26:678-684.
8. Ngong IN, Fru-Cho J, Yung MA, Akoachere JKT. Prevalence, antimicrobial susceptibility pattern and associated risk factors for urinary tract infections in pregnant women attending ANC in some integrated health centers in the Buea Health district. BMC Pregnancy Childbirth. 2021;21:673-674.
9. Al Yousef SA, Younis S, Farrag E, Moussa HS, Bayoumi FS, Ali AM. Clinical and laboratory profile of urinary tract infections associated with extended spectrum β -lactamase producing *Escherichia coli* and

- Klebsiella pneumoniae*. Annals of Clin and Laboratory Sci. 2016;46(4):393-400.
10. World Medical Association (WMA). Declaration of Helsinki. Ethical principles for Medical Research involving Human Subjects. Note of Clarification on paragraph 30 by the WMA General Assembly, Tokyo. 2004;9-10.
 11. Peter IU, Emelda NC, Chukwu EB, Ngwu JN, Uzoeto HO, Moneth EC, Stella AO, Edemekong CI, Uzoamaka EP, Nwuzo AC, Iroha IR. Molecular detection of bone sialoprotein-binding protein (*bbp*) genes among clinical isolates of methicillin resistant *Staphylococcus aureus* from hospitalized orthopedic wound patients. Asian J Orthopaedic Res. 2022;8(3):1-9.
 12. Edemekong, CI, Iroha IR, Thompson, MD, Okolo, IO., Uzoeto HO, Ngwu JN, Mohammed ID, Chukwu EB, Nwuzo AC, Okike BM, Okolie SO, Peter IU. Phenotypic characterization and antibiogram of non-oral bacteria isolates from patients attending dental clinic at Federal College of Dental Technology and Therapy Medical Center Enugu. Int J Pathog Res. 2022;11(2):7-19.
 13. Iroha IR, Orji JO, Onwa NC, Nwuzo AC, Okonkwo EC, Ibiom EO, Nwachi AC, Afuikwa FN, Agah VM, Ejikeugwu EPC, Agumah NB, Moses IB, Ugbo E, Ukpai EG, Nwakaeze E A, Oke B, Ogbu L and Nwunna E. Microbiology practical handbook. (Editor; Ogbu. O), 1st Edition. Charlieteximage Africa (CiAfrica Press). 2019:344.
 14. Edemekong CI, Uzoeto HO, Mbong EO, Ikusika BA, Didiugwu, CM, Ngwu JN, NseAbasi PL, Ntekpe ME, Mohammed ID, John-Onwe BN, Alagba EE, Obodoechi IF, Joseph OV, Ogbonna IP, Ubom IJ, Peter IU. Molecular characterization and bioassay of soil *Actinomycetes* strains on multidrug resistant bacteria. IOSR J Biotechnol Biochem. 2022;(1):6-11.
 15. Ogba RC, Nomeh OL, Edemekong CI, Nwuzo AC, Akpu, PO, Peter IU, Iroha IR. Molecular Characterization of Carbapenemase Encoding Genes in *Pseudomonas aeruginosa* from Tertiary Healthcare in South Eastern Nigeria. Asian J Bio Genet Mol Biol. 2022; 12(4): 161-168.
 16. Wang B, Pan F, Wang C, Zhao W, Sun Y, Zhang T, Shi Y, Zhang H. Molecular epidemiology of carbapenem-resistant *Klebsiella pneumoniae* in a paediatric hospital in China. Int J Infect Dis. 2020;93:311–319.
 17. Ferreira RL, da Silva BCM, Rezende GS, Nakamura-Silva R, Pitondo-Silva A, Campanini EB, Brito MCA, da Silva EML, Freire CCM, Cunha AF, Pranchevicius MC. High prevalence of multidrug-resistant *Klebsiella pneumoniae* harboring several virulence and beta-lactamase encoding genes in a Brazilian Intensive Care Unit. Front Microbiol. 2019;9:31-98.
 18. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD. Novel carbapenem-hydrolyzing β -lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. J Antimicrob Agent Chemother. 2001;45:1151–1161.
 19. Chen LF, Anderson DJ, Paterson DL. Overview of the epidemiology and the threat of *Klebsiella pneumoniae* carbapenemases (KPC) resistance. Infect Drug Resist. 2012; 5:133–41.
 20. Mohammed Y, Zailani SB, Onipede AO. Characterization of KPC, NDM and VIM type carbapenem resistance enterobacteriaceae from North Eastern Nigeria. J Bio Med. 2015;3:100–7.
 21. Wang Q, Wang X, Wang J, Ouyang P, Jin C, Wang R. Phenotypic and genotypic characterization of carbapenem-resistant enterobacteriaceae: Data from a longitudinal large-scale CRE study in China (2012–2016). Clin Infect Dis J. 2018;67(2):196–205.
 22. Olalekana A, Onwugambab F, Iwalokunc B, Mellmann A, Beckerb K, Schaumburg F. High Proportion of Carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae* among Extended-spectrum β -lactamase-producers in Nigerian Hospitals. J Glob Antimicrob Resist. 2020; 21:8–12.
 23. Aminu A, Daneji IM, Yusuf MA, Jalo RI, Tsiga-Ahmed FI, Yahaya M. Carbapenem-resistant *Enterobacteriaceae* Infections among Patients Admitted to Intensive Care Units in Kano, Nigeria. Sahel Med J. 2021; 24:1-9.
 24. Thapa A, Upreti MK, Bimali NK, Shrestha B, Sah AK, Nepal K, Dhungel B, Adhikari S, Adhikari N, Lekhak B, Rijal KR. Detection of NDM variants (*bla*NDM-1, *bla*NDM-2, *bla*NDM-3) from carbapenem-resistant *Escherichia coli* and *Klebsiella pneumoniae*: First report from Nepal. Infect and Drug Resist. 2022; 15 4419–4434.

25. Zhang Q, Lv L, Huang X, Huang Y, Zhuang Z, Lu J. Rapid increase in carbapenemase-producing enterobacteriaceae in retail meat driven by the spread of the carrying IncX3 plasmid in China from 2016 to 2018. *J Antimicrob Agent Chemother.* 2019;63(8):56-78.
26. Marques C, Belas A, Aboim C, Cavaco-Silva P, Trigueiro G, Gama LT. Evidence of sharing of *Klebsiella pneumoniae* strains between healthy companion animals and cohabiting humans. *J Clin Microbiol Infect Dis.* 2019;57(6):234-456.
27. Zhang F, Xie L, Wang X, Han L, Guo X, Ni Y. Further Spread of bla NDM-5 in Enterobacteriaceae via IncX3 plasmids in Shanghai, China. *Front Microbiol.* 2016; 7:424-425.
28. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B. Epidemiology of carbapenem-resistant enterobacteriaceae infections: Report from the China CRE Network. *J Antimicrob Agent Chemother.* 2018;62(2):23-45.
29. Alhazmi W, Al-Jabri A, Al-Zahrani I. The molecular characterization of nosocomial carbapenem-resistant *Klebsiella pneumoniae* co-harboring blaNDM and blaOXA-48 in Jeddah. *Microbiol Res.* 2022;13:753–764.
30. Shibl A, Al-Agamy M, Memish Z, Senok A, Khader SA, Assiri A. The emergence of OXA-48- and NDM-1-positive *Klebsiella pneumoniae* in Riyadh, Saudi Arabia. *Int J Infect Dis.* 2013;17:1130–1133.
31. Shibl A, Senok A, Memish Z. Infectious diseases in the Arabian Peninsula and Egypt. *J Clin Microbiol Infect Dis.* 2012;18:1068–80.
32. Nordmann P, Naas T, Poirel L. Global Spread of Carbapenemase-producing enterobacteriaceae. *Emerg Infect Dis.* 2011;17:1791–8.
33. Alizadeh N, Rezaee MA, Kafil HS, Hasani A, Barhaghi MHS, Milani M, Sefidan FY, Memar MY, Lalehzadeh A, Ghotaslou R. Evaluation of resistance mechanisms in carbapenem-resistant enterobacteriaceae. *Infect Drug Resist.* 2020;13:1377–1385.
34. Potron A, Poirel L, Rondinaud E, Nordmann P. Intercontinental spread of OXA-48 β -lactamase-producing enterobacteriaceae over a 11-year period, 2001 to 2011. *Euro Surveill.* 2013;18:20549.
35. Poirel L, Carbonnelle E, Bernabeu S, Gutmann L, Rotimi V, Nordmann P. Importation of OXA-48-producing *Klebsiella pneumoniae* from Kuwait. *J Antimicrob Agent Chemother.* 2012;67:2051–2052.
36. Beyrouthy R, Robin F, Cougnoux A, Dalmaso G, Darfeuille-Michaud A, Mallat H. Chromosome-mediated OXA-48 carbapenemase in highly virulent *Escherichia coli*. *J Antimicrob Agent Chemother.* 2013;68:1558–1561.
37. Beyrouthy R, Robin F, Dabboussi F, Mallat H, Hamze M, Bonnet R. Carbapenemase and virulence factors of enterobacteriaceae in North Lebanon between 2008 and 2012: Evolution via Endemic Spread of OXA-48. *J Antimicrob Agent Chemother.* 2014;69:2699–2705.
38. de Toro M, Fernandez J, Garcia V, Mora A, Blanco J, De La Cruz F. Whole genome sequencing, molecular typing and *in vivo* virulence of OXA-48-producing *Escherichiacoli* isolates including ST131 H30-Rx, H22 and H41 subclones. *J Scientific Report.* 2017;7:12103-12109.
39. Hashemizadeh Z, Hosseinzadeh Z, Azimzadeh N, Motamedifar M. Dissemination pattern of multidrug resistant carbapenemase producing *Klebsiella pneumoniae* isolates using pulsed-field gel electrophoresis in Southwestern Iran. *Infect Drug Resist.* 2020;13:921–929.
40. Tian D, Pan F, Wang C, Sun Y, Zhang H. Resistance phenotype and clinical molecular epidemiology of carbapenem-resistant *Klebsiella pneumoniae* among pediatric patients in Shanghai. *Infect and Drug Resist.* 2018;11:1935–43.
41. Saavedra SY, Bernal JF, Montilla-Escudero E, Arévalo SA, Andrés Prada D, Valencia MF, Moreno J, Hidalgo AM, García-Vega ÁS, Abrudan M, Argimón S, Kekre M, Underwood A, Aanensen DM, Duarte C, Donado-Godoy P, NIHR Global Health Research Unit on Genomic Surveillance of Antimicrobial Resistance. Complexity of genomic epidemiology of carbapenem-resistant *Klebsiella pneumoniae* isolates in Colombia Urges the reinforcement of whole genome sequencing-based surveillance programs. *Clinical Infectious Diseases.* 2021;73(4):290–9.
42. Murugan MS, Sinha DK, Vinodh Kumar OR, Yadav AK, Pruthivishree BS, Vadhana P, Nirupama KR, Bhardwaj M, Singh BR. Epidemiology of carbapenem resistant

- Escherichia coli* and First Report of blaVIM carbapenemases gene in Calves from India. Epidemiol Infect. 2019;147:159, 1–5.
43. Lee K, Yong D, Choi YS, Yum JH, Kim J M, Woodford N, Livermore DM, Chong Y. Reduced imipenem susceptibility in *Klebsiella pneumoniae* clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases Co-mediated by Porin Loss. Int J Antimicrob Agents. 2007;29:201-206.
44. Ding H, Yang Y, Lu Q, Wang Y, Chen Y, Deng L, Wang A, Deng Q, Zhang H, Wang C. The prevalence of plasmid-mediated AmpC beta-lactamases among clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* from Five Children's Hospitals in China. Euro J Clin Microbiol Infect Dis. 2008;27:915-921.
45. Yamada Y, Ishii Y, Kouyama Y, Katho M, Odashiro R, Yamahata K, Tateda K, Yamaguchi K, Suwabe A. Characterization of *Klebsiella pneumoniae* producing SHV-12 and DHA-1 beta-lactamases accompanied by carbapenem resistance during hospitalization in a Chronic Care Ward in Japan. J Chemother. 2008;21: 445-447.

© 2023 Nomeh et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/95266>